Current medical news and unique business news for anyone who cares about the healthcare industry.
UCB fined for off-label use: Belgian drug company UCB must pay more than $34 million in fines after pleading guilty to marketing its blockbuster epilepsy drug Keppra for an off-label use. UCB had promoted the drug for treating migraines, an unapproved indication for the product. Keppra is UCB’s top-selling product generating more than $1.37 billion in 2010 revenue, according to Bloomberg News.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
New prostate cancer risk? The FDA warns that some drugs to treat the prostate and baldness may raise the risk of the most serious form of prostate cancer. But Forbes checked with American Medical Society Chief Medical Officer Otis Brawley, a physician who treats prostate cancer. Brawley disagrees.
Flu shots reach all time high: The Centers for Disease Control and Prevention said that more people got flu shots in the last year than ever before, reports MedPage today.
Pharma/university partnership: Roche enters a partnership with UCLA on stem cell and cancer research.
Dealflow: Med dev company Access Scientific raises $10 million led by private equity firm CAC; CAS Medical Systems raises $15 million to develop its high-tech blood monitors.
